- Home
- SOLS vs AXSM Comparison
SOLS vs AXSM Comparison
Compare SOLS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOLS | AXSM |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | 4400 | 925 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 12.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SOLS | AXSM |
|---|---|---|
| Price | $80.35 | $226.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $79.25 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.1M | 825.0K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.36 | $57.24 |
| Revenue Next Year | $5.64 | $55.88 |
| P/E Ratio | $54.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.43 | $96.09 |
| 52 Week High | $90.80 | $235.92 |
Technical Indicators
Market Signals| Indicator | SOLS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 68.70 |
| Support Level | $76.92 | $148.87 |
| Resistance Level | $83.53 | $234.29 |
| Average True Range (ATR) | 4.11 | 10.53 |
| MACD | -0.20 | 0.32 |
| Stochastic Oscillator | 27.81 | 82.76 |
Price Performance
Historical ComparisonAbout SOLS Solstice Advanced Materials Inc.
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.